Weibo (WB) Reports In-Line Q1 EPS, Beats on Revenues; Strong Q2 Revenue Guidance

Weibo (NASDAQ: WB) reported Q1 EPS of $0.21, in-line with the analyst estimate of $0.21. Revenue for the quarter came in at $199.2 million versus the consensus estimate of $186.85 million.

GUIDANCE:

Weibo sees Q2 2017 revenue of $240-250 million, versus the consensus of $228.46 million

Business Outlook

For the second quarter of 2017, Weibo estimates that its net revenues to be between $240 million and $250 million, which assumes a RMB to US dollar average exchange rate of 6.9. This forecast reflects Weibo\'s current and preliminary view, which is subject to change.

First Quarter 2017 Highlights

• Net revenues totaled $199.2 million, an increase of 67% year-over-year, exceeding the Company's guidance between $185 million and $190 million.
• Advertising and marketing revenues were $169.3 million, an increase of 71% year-over-year.
• Other revenues were $29.9 million, an increase of 49% year-over-year.
• Net income attributable to Weibo was $46.9 million, an increase of 561% year-over-year, and diluted net income per share was $0.21, compared to $0.03 for the same period last year.
• Non-GAAP net income attributable to Weibo was $57.8 million, an increase of 254% year-over-year, and non-GAAP diluted net income per share was $0.26, compared to $0.07 for the same period last year.
• Adjusted EBITDA was $70.5 million, an increase of 272% year-over-year, or 35% of net revenues, compared to 16% for the same period last year.
• Monthly active users ("MAUs") in March 2017 was 340 million, an increase of 30% year-over-year, 91% of which were mobile users. Average daily active users in March 2017 was 154 million, an increase of 28% year-over-year.

For earnings history and earnings-related data on Weibo (WB) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Hermès can regain momentum despite China weakness, Jefferies says
• Pfizer lung cancer drug misses survival goal in Phase 3 trial